It checks today's price at every store, compares the alternatives and answers in about a minute.
This is a six-month telehealth weight-loss program built around once-weekly tirzepatide injections at 10 to 15 mg per week. Tirzepatide is a dual GLP-1 and GIP receptor agonist that slows gastric emptying and curbs appetite, and it is the active ingredient in Zepbound and Mounjaro. The program bundles an initial telehealth visit, the prescription and medication if approved, and unlimited physician support. It suits people already on tirzepatide or starting at a higher dose who want six months of treatment and steady access to a prescriber, rather than someone starting from scratch at the lowest dose.
In stockReturn policy
Buyers rate the program 4.4 out of 5 and mostly describe a smooth process, responsive physicians and steady weight loss with appetite well controlled. Several note few side effects when the dose is raised slowly.
This is a six-month high dose program built around tirzepatide, a once-weekly injection prescribed for obesity along with diet and exercise. Tirzepatide is a dual GLP-1 and GIP receptor agonist. It slows digestion by delaying gastric emptying, so you feel fuller longer. It may lead to fewer cravings and feeling full after smaller meals.
The program is for people starting at a higher dose or already on medication. It covers any dose from 10 mg per week up to 15 mg per week. It includes an initial telehealth visit, a prescription and medication if approved, and unlimited physician support.
